| Work Detail |
The development of the anticipated bulk drug park in Jambusar, Gujarat is likely to be expedited, as the Gujarat government is gearing up to initiate the tendering process for the common facilities and land allotment to the companies.
The proposed 2,000-acre park project will enable the indigenous production of key starting materials (KSM), active pharma ingredients (API) and pharma intermediates, which are imported from China. Manufacturing of around 51 products including Amoxicillin, Azythromycin, Cephalexin, Vitamin B1 and B6 and Acyclovir will be taken up.
Common facilities include nitrogen utility, common effluent treatment plant (CETP), solvent recovery, training facility, testing and research facility and common steam utility.
As per Indian Drug Manufacturers Association (IDMA) estimates, the park will be home to 400 companies and attract an investment of over Rs 8,000 crore. The state government is expected to ito the companies soon. The Central government will set up three bulk drug parks in the country including the one in Jambusar to reduce bulk drug import dependence.
The Indian pharma market, which saw a 5.1 percent growth in exports in the first quarter of FY24 has witnessed increased dependence on raw material over the years.To this end, the PLI scheme and bulk drug parks are expected to significantly reduce API imports in the coming years. |
